AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC, whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy, or CRT, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- FDA Cellular, Tissue & Gene Therapies Advisory Committee holds virtual meeting
- Soros boosts stake in AstraZeneca, exits Apple position
- AstraZeneca put volume heavy and directionally bearish
- Reporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics
- AstraZeneca Reports Strong Growth in Q3 2024